Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The company has developed notable medications such as Prozac for depression, Humalog for diabetes, and Mounjaro for type 2 diabetes. Looking closer, Eli Lilly ... Inc. With headquarters in the ...

FILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis ... the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while ...

Tinder Gold just got a whole lot cheaper — from $108 down to $39.97 FILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017. (AP Photo ...

Eli Lilly’s profit doubled in ... better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter ...